Leqembi and Alzheimer’s: What to Know About the New Drug, Treatment and Benefits
As the F.D.A. considers a new Alzheimer’s medication, we asked experts how the rollout of a similar drug has gone.
Call for more information
888-531-0245
info@siii-clinical.com
From research laboratories to clinical settings, SIII integrates the technologies, resources, and expertise our customers need to rise to the next opportunity. SIII is dedicated to exploring and researching the processes and scientific mechanisms underlying the world we live in.